Atea Pharmaceuticals (AVIR) EBITDA (2019 - 2026)

Atea Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$48.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 22.97% year-over-year to -$48.0 million; the TTM figure through Mar 2026 stood at -$189.9 million (down 17.06% YoY), while the FY2025 annual figure was -$180.9 million, up 6.25% from the prior year.
• EBITDA for Q1 2026 stood at -$48.0 million, up from -$54.9 million in the prior quarter.
• The five-year high for EBITDA was -$16.3 million in Q3 2022, with the low at -$69.8 million in Q1 2024.
• The 5-year median for EBITDA is -$41.3 million (2025), against an average of -$42.2 million.
• The sharpest annual moves came in 2022 and 2025: EBITDA plunged 471.76% in 2022, then jumped 44.07% in 2025.
• Atea Pharmaceuticals' EBITDA stood at -$39.9 million in 2022, then dropped by 16.73% to -$46.6 million in 2023, then grew by 16.2% to -$39.0 million in 2024, then sank by 40.76% to -$54.9 million in 2025, then rose by 12.61% to -$48.0 million in 2026.
• Business Quant data shows AVIR's EBITDA at -$48.0 million in Q1 2026, -$54.9 million in Q4 2025, and -$45.6 million in Q3 2025.